{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:57:34Z","timestamp":1781099854348,"version":"3.54.1"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["MedScience"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s11684-025-1184-9","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T09:54:39Z","timestamp":1765965279000},"page":"1236-1251","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Plasma cell development-based prediction of prognosis and treatment response in individual multiple myeloma"],"prefix":"10.1007","volume":"19","author":[{"given":"Sitao","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Yao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayaz Ali","family":"Samo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pengli","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qinglan","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiuyi","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huijuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenming","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuzhang","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaolong","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,12,17]]},"reference":[{"issue":"29","key":"1184_CR1","doi-asserted-by":"publisher","first-page":"3406","DOI":"10.1200\/JCO.21.02614","volume":"40","author":"M D\u2019Agostino","year":"2022","unstructured":"D\u2019Agostino M, Cairns DA, Lahuerta JJ, Wester R, Bertsch U, Waage A, Zamagni E, Mateos MV, Dall\u2019Olio D, van de Donk NWCJ, Jackson G, Rocchi S, Salwender H, Blad\u00e9 Creixenti J, van der Holt B, Castellani G, Bonello F, Capra A, Mai EK, D\u00fcrig J, Gay F, Zweegman S, Cavo M, Kaiser MF, Goldschmidt H, Hern\u00e1ndez Rivas JM, Larocca A, Cook G, San-Miguel JF, Boccadoro M, Sonneveld P. Second Revision of the international staging system (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project. J Clin Oncol 2022; 40(29): 3406\u20133418","journal-title":"J Clin Oncol"},{"issue":"26","key":"1184_CR2","doi-asserted-by":"publisher","first-page":"2863","DOI":"10.1200\/JCO.2015.61.2267","volume":"33","author":"A Palumbo","year":"2015","unstructured":"Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, Richardson P, Caltagirone S, Lahuerta JJ, Facon T, Bringhen S, Gay F, Attal M, Passera R, Spencer A, Offidani M, Kumar S, Musto P, Lonial S, Petrucci MT, Orlowski RZ, Zamagni E, Morgan G, Dimopoulos MA, Durie BGM, Anderson KC, Sonneveld P, San Miguel J, Cavo M, Rajkumar SV, Moreau P. Revised international staging system for multiple myeloma: a report from International Myeloma Working Group. J Clin Oncol 2015; 33(26): 2863\u20132869","journal-title":"J Clin Oncol"},{"issue":"7","key":"1184_CR3","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1182\/blood-2018-09-825331","volume":"133","author":"C Pawlyn","year":"2019","unstructured":"Pawlyn C, Davies FE. Toward personalized treatment in multiple myeloma based on molecular characteristics. Blood 2019; 133(7): 660\u2013675","journal-title":"Blood"},{"issue":"41","key":"1184_CR4","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1200\/EDBK_320105","volume":"41","author":"J Caro","year":"2021","unstructured":"Caro J, Al Hadidi S, Usmani S, Yee AJ, Raje N, Davies FE. How to treat high-risk myeloma at diagnosis and relapse. Am Soc Clin Oncol Educ Book 2021; 41(41): 291\u2013309","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"11","key":"1184_CR5","doi-asserted-by":"publisher","first-page":"2119","DOI":"10.1038\/leu.2015.209","volume":"29","author":"SZ Usmani","year":"2015","unstructured":"Usmani SZ, Rodriguez-Otero P, Bhutani M, Mateos MV, Miguel JS. Defining and treating high-risk multiple myeloma. Leukemia 2015; 29(11): 2119\u20132125","journal-title":"Leukemia"},{"issue":"11","key":"1184_CR6","doi-asserted-by":"publisher","first-page":"2406","DOI":"10.1038\/leu.2012.127","volume":"26","author":"R Kuiper","year":"2012","unstructured":"Kuiper R, Broyl A, de Knegt Y, van Vliet MH, van Beers EH, van der Holt B, el Jarari L, Mulligan G, Gregory W, Morgan G, Goldschmidt H, Lokhorst HM, van Duin M, Sonneveld P. A gene expression signature for high-risk multiple myeloma. Leukemia 2012; 26(11): 2406\u20132413","journal-title":"Leukemia"},{"issue":"19","key":"1184_CR7","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.1200\/JCO.18.00776","volume":"37","author":"A Perrot","year":"2019","unstructured":"Perrot A, Lauwers-Cances V, Tournay E, Hulin C, Chretien ML, Royer B, Dib M, Decaux O, Jaccard A, Belhadj K, Brechignac S, Fontan J, Voillat L, Demarquette H, Collet P, Rodon P, Sohn C, Lifermann F, Orsini-Piocelle F, Richez V, Mohty M, Macro M, Minvielle S, Moreau P, Leleu X, Facon T, Attal M, Avet-Loiseau H, Corre J. Development and validation of a cytogenetic prognostic index predicting survival in multiple myeloma. J Clin Oncol 2019; 37(19): 1657\u20131665","journal-title":"J Clin Oncol"},{"issue":"5","key":"1184_CR8","doi-asserted-by":"publisher","first-page":"1122","DOI":"10.1038\/leu.2013.313","volume":"28","author":"SK Kumar","year":"2014","unstructured":"Kumar SK, Dispenzieri A, Lacy MQ, Gertz MA, Buadi FK, Pandey S, Kapoor P, Dingli D, Hayman SR, Leung N, Lust J, McCurdy A, Russell SJ, Zeldenrust SR, Kyle RA, Rajkumar SV. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia 2014; 28(5): 1122\u20131128","journal-title":"Leukemia"},{"issue":"24","key":"1184_CR9","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1056\/NEJMoa043445","volume":"352","author":"PG Richardson","year":"2005","unstructured":"Richardson PG, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D, San-Miguel JF, Blad\u00e9 J, Boccadoro M, Cavenagh J, Dalton WS, Boral AL, Esseltine DL, Porter JB, Schenkein D, Anderson KC. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352(24): 2487\u20132498","journal-title":"N Engl J Med"},{"issue":"22","key":"1184_CR10","doi-asserted-by":"publisher","first-page":"5952","DOI":"10.1158\/1078-0432.CCR-20-0742","volume":"26","author":"J Ubels","year":"2020","unstructured":"Ubels J, Sonneveld P, van Vliet MH, de Ridder J. Gene networks constructed through simulated treatment learning can predict proteasome inhibitor benefit in multiple myeloma. Clin Cancer Res 2020; 26(22): 5952\u20135961","journal-title":"Clin Cancer Res"},{"issue":"8","key":"1184_CR11","doi-asserted-by":"publisher","first-page":"3177","DOI":"10.1182\/blood-2006-09-044974","volume":"109","author":"G Mulligan","year":"2007","unstructured":"Mulligan G, Mitsiades C, Bryant B, Zhan F, Chng WJ, Roels S, Koenig E, Fergus A, Huang Y, Richardson P, Trepicchio WL, Broyl A, Sonneveld P, Shaughnessy JD Jr, Leif Bergsagel P, Schenkein D, Esseltine DL, Boral A, Anderson KC. Gene expression profiling and correlation with outcome in clinical trials of the proteasome inhibitor bortezomib. Blood 2007; 109(8): 3177\u20133188","journal-title":"Blood"},{"issue":"21","key":"1184_CR12","doi-asserted-by":"publisher","first-page":"3518","DOI":"10.1200\/JCO.2008.18.3087","volume":"27","author":"PG Richardson","year":"2009","unstructured":"Richardson PG, Xie W, Mitsiades C, Chanan-Khan AA, Lonial S, Hassoun H, Avigan DE, Oaklander AL, Kuter DJ, Wen PY, Kesari S, Briemberg HR, Schlossman RL, Munshi NC, Heffner LT, Doss D, Esseltine DL, Weller E, Anderson KC, Amato AA. Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy. J Clin Oncol 2009; 27(21): 3518\u20133525","journal-title":"J Clin Oncol"},{"issue":"5","key":"1184_CR13","doi-asserted-by":"publisher","first-page":"e124","DOI":"10.1200\/JCO.2010.32.1869","volume":"29","author":"J Mehta","year":"2011","unstructured":"Mehta J. Total therapy 2 in treatment of multiple myeloma: questions about gene expression profiling and treatment-related mortality. J Clin Oncol 2011; 29(5): e124","journal-title":"J Clin Oncol"},{"issue":"10","key":"1184_CR14","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1056\/NEJMoa053583","volume":"354","author":"B Barlogie","year":"2006","unstructured":"Barlogie B, Tricot G, Anaissie E, Shaughnessy J, Rasmussen E, van Rhee F, Fassas A, Zangari M, Hollmig K, Pineda-Roman M, Lee C, Talamo G, Thertulien R, Kiwan E, Krishna S, Fox M, Crowley J. Thalidomide and hematopoietic-cell transplantation for multiple myeloma. N Engl J Med 2006; 354(10): 1021\u20131030","journal-title":"N Engl J Med"},{"issue":"1","key":"1184_CR15","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1182\/blood-2005-01-0034","volume":"106","author":"PL Bergsagel","year":"2005","unstructured":"Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J Jr. Cyclin D dysregulation: an early and unifying pathogenic event in multiple myeloma. Blood 2005; 106(1): 296\u2013303","journal-title":"Blood"},{"issue":"6","key":"1184_CR16","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1182\/blood-2005-11-013458","volume":"108","author":"F Zhan","year":"2006","unstructured":"Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD Jr. The molecular classification of multiple myeloma. Blood 2006; 108(6): 2020\u20132028","journal-title":"Blood"},{"issue":"14","key":"1184_CR17","doi-asserted-by":"publisher","first-page":"2543","DOI":"10.1182\/blood-2009-12-261032","volume":"116","author":"A Broyl","year":"2010","unstructured":"Broyl A, Hose D, Lokhorst H, de Knegt Y, Peeters J, Jauch A, Bertsch U, Buijs A, Stevens-Kroef M, Beverloo HB, Vellenga E, Zweegman S, Kersten MJ, van der Holt B, el Jarari L, Mulligan G, Goldschmidt H, van Duin M, Sonneveld P. Gene expression profiling for molecular classification of multiple myeloma in newly diagnosed patients. Blood 2010; 116(14): 2543\u20132553","journal-title":"Blood"},{"issue":"9","key":"1184_CR18","doi-asserted-by":"publisher","first-page":"1878","DOI":"10.1038\/s41588-024-01853-0","volume":"56","author":"S Skerget","year":"2024","unstructured":"Skerget S, Penaherrera D, Chari A, Jagannath S, Siegel DS, Vij R, Orloff G, Jakubowiak A, Niesvizky R, Liles D, Berdeja J, Levy M, Wolf J, Usmani SZ, Rifkin R, Meehan K, Benson D, Zonder J, Ascensao J, Gasparetto C, Hern\u00e1ndez M, Trudel S, Dakhil S, Bahlis N, Paganini JV, Rios P, Sampol A, Mannem S, Silbermann R, Lunning M, Chu M, Milner C, Harroff A, Graham M, Shao S, Dodlapati J, de Larrea CF, Klein L, Kuzma C, Fonseca R, Azaceta G, Granell M, Martinez-Chamorro C, Balaraman R, Silva C, Chinea A, Costello C, Kambhampati S, Lewis DQ, Grossbard M, Yost K, Robles R, Sebag M, Harris W, Ngaiza J, Bar M, Shieh M, Min F, Onitilo A, Volterra F, Wachsman W, Yalamachili M, Abella E, Anderson L, Bargay J, Hassoun H, Hsu G, Kaya H, Menter A, Patel D, Richards D, Solomon W, Anderson R, Chandra S, Conde M, Girnius S, Matkiwsky M, Krsnik I, Kumar S, Oriol A, Rodr\u00edguez P, Roy V, Srinivas S, Steis R, Christofferson AW, Nasser S, Aldrich JL, Legendre C, Benard B, Miller C, Turner B, Kurdoglu A, Washington M, Yellapantula V, Adkins JR, Cuyugan L, Boateng M, Helland A, Kyman S, McDonald J, Reiman R, Stephenson K, Tassone E, Blanski A, Livermore B, Kirchhoff M, Rohrer DC, D\u2019Agostino M, Gambella M, Collison K, Stumph J, Kidd P, Donnelly A, Zaugg B, Toone M, McBride K, DeRome M, Rogers J, Craig D, Liang WS, Gutierrez NC, Jewell SD, Carpten J, Anderson KC, Cho HJ, Auclair D, Lonial S, Keats JJ. Comprehensive molecular profiling of multiple myeloma identifies refined copy number and expression subtypes. Nat Genet 2024; 56(9): 1878\u20131889","journal-title":"Nat Genet"},{"issue":"6","key":"1184_CR19","doi-asserted-by":"publisher","first-page":"2276","DOI":"10.1182\/blood-2006-07-038430","volume":"109","author":"JD Shaughnessy Jr","year":"2007","unstructured":"Shaughnessy JD Jr, Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood 2007; 109(6): 2276\u20132284","journal-title":"Blood"},{"issue":"9","key":"1184_CR20","doi-asserted-by":"publisher","first-page":"e443","DOI":"10.1016\/S2352-3026(17)30143-6","volume":"4","author":"M Bhutani","year":"2017","unstructured":"Bhutani M, Zhang Q, Friend R, Voorhees PM, Druhan LJ, Barlogie B, Sonneveld P, Morgan GJ, Symanowski JT, Avalos BR, Copelan EA, Usmani SZ. Investigation of a gene signature to predict response to immunomodulatory derivatives for patients with multiple myeloma: an exploratory, retrospective study using microarray datasets from prospective clinical trials. Lancet Haematol 2017; 4(9): e443\u2013e451","journal-title":"Lancet Haematol"},{"issue":"13","key":"1184_CR21","doi-asserted-by":"publisher","first-page":"3512","DOI":"10.1182\/blood-2010-12-328252","volume":"118","author":"JD Shaughnessy Jr","year":"2011","unstructured":"Shaughnessy JD Jr, Qu P, Usmani S, Heuck CJ, Zhang Q, Zhou Y, Tian E, Hanamura I, van Rhee F, Anaissie E, Epstein J, Nair B, Stephens O, Williams R, Waheed S, Alsayed Y, Crowley J, Barlogie B. Pharmacogenomics of bortezomib test-dosing identifies hyperexpression of proteasome genes, especially PSMD4, as novel high-risk feature in myeloma treated with Total Therapy 3. Blood 2011; 118(13): 3512\u20133524","journal-title":"Blood"},{"issue":"20","key":"1184_CR22","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1182\/blood-2018-05-849893","volume":"132","author":"MA Chapman","year":"2018","unstructured":"Chapman MA, Sive J, Ambrose J, Roddie C, Counsell N, Lach A, Abbasian M, Popat R, Cavenagh JD, Oakervee H, Streetly MJ, Schey S, Koh M, Willis F, Virchis AE, Crowe J, Quinn MF, Cook G, Crawley CR, Pratt G, Cook M, Braganza N, Adedayo T, Smith P, Clifton-Hadley L, Owen RG, Sonneveld P, Keats JJ, Herrero J, Yong K. RNA-seq of newly diagnosed patients in the PADIMAC study leads to a bortezomib\/lenalidomide decision signature. Blood 2018; 132(20): 2154\u20132165","journal-title":"Blood"},{"issue":"11","key":"1184_CR23","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1200\/JCO.23.01277","volume":"42","author":"F Maura","year":"2024","unstructured":"Maura F, Rajanna AR, Ziccheddu B, Poos AM, Derkach A, Maclachlan K, Durante M, Diamond B, Papadimitriou M, Davies F, Boyle EM, Walker B, Hultcrantz M, Silva A, Hampton O, Teer JK, Siegel EM, Bolli N, Jackson GH, Kaiser M, Pawlyn C, Cook G, Kazandjian D, Stein C, Chesi M, Bergsagel L, Mai EK, Goldschmidt H, Weisel KC, Fenk R, Raab MS, Van Rhee F, Usmani S, Shain KH, Weinhold N, Morgan G, Landgren O. Genomic classification and individualized prognosis in multiple myeloma. J Clin Oncol 2024; 42(11): 1229\u20131240","journal-title":"J Clin Oncol"},{"issue":"10","key":"1184_CR24","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1038\/nrc.2017.69","volume":"17","author":"CC Maley","year":"2017","unstructured":"Maley CC, Aktipis A, Graham TA, Sottoriva A, Boddy AM, Janiszewska M, Silva AS, Gerlinger M, Yuan Y, Pienta KJ, Anderson KS, Gatenby R, Swanton C, Posada D, Wu CI, Schiffman JD, Hwang ES, Polyak K, Anderson ARA, Brown JS, Greaves M, Shibata D. Classifying the evolutionary and ecological features of neoplasms. Nat Rev Cancer 2017; 17(10): 605\u2013619","journal-title":"Nat Rev Cancer"},{"issue":"21","key":"1184_CR25","doi-asserted-by":"publisher","first-page":"8685","DOI":"10.1073\/pnas.0701361104","volume":"104","author":"KI Goh","year":"2007","unstructured":"Goh KI, Cusick ME, Valle D, Childs B, Vidal M, Barabasi AL. The human disease network. Proc Natl Acad Sci USA 2007; 104(21): 8685\u20138690","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1184_CR26","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/nri2217","volume":"8","author":"U Klein","year":"2008","unstructured":"Klein U, Dalla-Favera R. Germinal centres: role in B-cell physiology and malignancy. Nat Rev Immunol 2008; 8(1): 22\u201333","journal-title":"Nat Rev Immunol"},{"issue":"3","key":"1184_CR27","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/nri3804","volume":"15","author":"NS De Silva","year":"2015","unstructured":"De Silva NS, Klein U. Dynamics of B cells in germinal centres. Nat Rev Immunol 2015; 15(3): 137\u2013148","journal-title":"Nat Rev Immunol"},{"issue":"8","key":"1184_CR28","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1002\/gcc.2","volume":"57","author":"AA Samo","year":"2018","unstructured":"Samo AA, Li J, Zhou M, Sun Y, Yang Y, Zhang Y, Li J, van Duin M, Lu X, Fan X. MCL1 gene co-expression module stratifies multiple myeloma and predicts response to proteasome inhibitor-based therapy. Genes Chromosomes Cancer 2018; 57(8): 420\u2013429","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"1184_CR29","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1038\/ni.2527","volume":"14","author":"V Peperzak","year":"2013","unstructured":"Peperzak V, Vikstrom I, Walker J, Glaser SP, LePage M, Coquery CM, Erickson LD, Fairfax K, Mackay F, Strasser A, Nutt SL, Tarlinton DM. Mcl-1 is essential for the survival of plasma cells. Nat Immunol 2013; 14(3): 290\u2013297","journal-title":"Nat Immunol"},{"issue":"14","key":"1184_CR30","doi-asserted-by":"publisher","first-page":"1969","DOI":"10.1182\/blood-2016-10-745059","volume":"129","author":"VA Gupta","year":"2017","unstructured":"Gupta VA, Matulis SM, Conage-Pough JE, Nooka AK, Kaufman JL, Lonial S, Boise LH. Bone marrow microenvironment-derived signals induce Mcl-1 dependence in multiple myeloma. Blood 2017; 129(14): 1969\u20131979","journal-title":"Blood"},{"issue":"21","key":"1184_CR31","doi-asserted-by":"publisher","first-page":"4168","DOI":"10.1182\/blood-2009-11-255620","volume":"115","author":"B Nair","year":"2010","unstructured":"Nair B, van Rhee F, Shaughnessy JD Jr, Anaissie E, Szymonifka J, Hoering A, Alsayed Y, Waheed S, Crowley J, Barlogie B. Superior results of Total Therapy 3 (2003\u201333) in gene expression profiling-defined low-risk multiple myeloma confirmed in subsequent trial 2006\u201366 with VRD maintenance. Blood 2010; 115(21): 4168\u20134173","journal-title":"Blood"},{"issue":"24","key":"1184_CR32","doi-asserted-by":"publisher","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","volume":"30","author":"P Sonneveld","year":"2012","unstructured":"Sonneveld P, Schmidt-Wolf IG, van der Holt B, El Jarari L, Bertsch U, Salwender H, Zweegman S, Vellenga E, Broyl A, Blau IW, Weisel KC, Wittebol S, Bos GMJ, Stevens-Kroef M, Scheid C, Pfreundschuh M, Hose D, Jauch A, van der Velde H, Raymakers R, Schaafsma MR, Kersten MJ, van Marwijk-Kooy M, Duehrsen U, Lindemann W, Wijermans PW, Lokhorst HM, Goldschmidt HM. Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial. J Clin Oncol 2012; 30(24): 2946\u20132955","journal-title":"J Clin Oncol"},{"issue":"12","key":"1184_CR33","doi-asserted-by":"publisher","first-page":"2410","DOI":"10.1038\/leu.2014.232","volume":"28","author":"CJ Heuck","year":"2014","unstructured":"Heuck CJ, Qu P, van Rhee F, Waheed S, Usmani SZ, Epstein J, Zhang Q, Edmondson R, Hoering A, Crowley J, Barlogie B. Five gene probes carry most of the discriminatory power of the 70-gene risk model in multiple myeloma. Leukemia 2014; 28(12): 2410\u20132413","journal-title":"Leukemia"},{"issue":"1","key":"1184_CR34","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1182\/blood.2020006731","volume":"137","author":"I Goicoechea","year":"2021","unstructured":"Goicoechea I, Puig N, Cedena MT, Burgos L, Cordon L, Vidriales MB, Flores-Montero J, Gutierrez NC, Calasanz MJ, Ramos MLM, Lara-Astiaso D, Vilas-Zornoza A, Alignani D, Rodriguez I, Sarvide S, Alameda D, Garc\u00e9s JJ, Rodriguez S, Fresquet V, Celay J, Garcia-Sanz R, Martinez-Lopez J, Oriol A, Rios R, Martin-Sanchez J, Martinez-Martinez R, Sarra J, Hernandez MT, de la Rubia J, Krsnik I, Moraleda JM, Palomera L, Bargay J, Martinez-Climent JA, Orfao A, Rosi\u00f1ol L, Mateos MV, Lahuerta JJ, Blade J, San Miguel J, Paiva B. Deep MRD profiling defines outcome and unveils different modes of treatment resistance in standard- and high-risk myeloma. Blood 2021; 137(1): 49\u201360","journal-title":"Blood"},{"issue":"11","key":"1184_CR35","doi-asserted-by":"publisher","first-page":"e1003323","DOI":"10.1371\/journal.pmed.1003323","volume":"17","author":"SA Danziger","year":"2020","unstructured":"Danziger SA, McConnell M, Gockley J, Young MH, Rosenthal A, Schmitz F, Reiss DJ, Farmer P, Alapat DV, Singh A, Ashby C, Bauer M, Ren Y, Smith K, Couto SS, van Rhee F, Davies F, Zangari M, Petty N, Orlowski RZ, Dhodapkar MV, Copeland WB, Fox B, Hoering A, Fitch A, Newhall K, Barlogie B, Trotter MWB, Hershberg RM, Walker BA, Dervan AP, Ratushny AV, Morgan GJ. Bone marrow microenvironments that contribute to patient outcomes in newly diagnosed multiple myeloma: A cohort study of patients in the Total Therapy clinical trials. PLoS Med 2020; 17(11): e1003323","journal-title":"PLoS Med"},{"issue":"14","key":"1184_CR36","doi-asserted-by":"publisher","first-page":"6975","DOI":"10.1073\/pnas.1814060116","volume":"116","author":"Y Zhang","year":"2019","unstructured":"Zhang Y, Li J, Yi K, Feng J, Cong Z, Wang Z, Wei Y, Wu F, Cheng W, Samo AA, Salomoni P, Yang Q, Huang Y, Kang C, Jiang T, Fan X. Elevated signature of a gene module coexpressed with CDC20 marks genomic instability in glioma. Proc Natl Acad Sci USA 2019; 116(14): 6975\u20136984","journal-title":"Proc Natl Acad Sci USA"},{"issue":"6411","key":"1184_CR37","doi-asserted-by":"publisher","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","volume":"362","author":"R Cristescu","year":"2018","unstructured":"Cristescu R, Mogg R, Ayers M, Albright A, Murphy E, Yearley J, Sher X, Liu XQ, Lu H, Nebozhyn M, Zhang C, Lunceford JK, Joe A, Cheng J, Webber AL, Ibrahim N, Plimack ER, Ott PA, Seiwert TY, Ribas A, McClanahan TK, Tomassini JE, Loboda A, Kaufman D. Pan-tumor genomic biomarkers for PD-1 checkpoint blockade-based immunotherapy. Science 2018; 362(6411): eaar3593","journal-title":"Science"},{"issue":"8","key":"1184_CR38","doi-asserted-by":"publisher","first-page":"2930","DOI":"10.1172\/JCI91190","volume":"127","author":"M Ayers","year":"2017","unstructured":"Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman DR, Albright A, Cheng JD, Kang SP, Shankaran V, Piha-Paul SA, Yearley J, Seiwert TY, Ribas A, McClanahan TK. IFN-gamma-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest 2017; 127(8): 2930\u20132940","journal-title":"J Clin Invest"},{"issue":"18","key":"1184_CR39","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1182\/blood-2018-09-874396","volume":"133","author":"T Facon","year":"2019","unstructured":"Facon T, Lee JH, Moreau P, Niesvizky R, Dimopoulos M, Hajek R, Pour L, Jurczyszyn A, Qiu L, Klippel Z, Zahlten-Kumeli A, Osman M, Paiva B, San-Miguel J. Carfilzomib or bortezomib with melphalan-prednisone for transplant-ineligible patients with newly diagnosed multiple myeloma. Blood 2019; 133(18): 1953\u20131963","journal-title":"Blood"},{"issue":"10","key":"1184_CR40","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1016\/S1470-2045(20)30452-6","volume":"21","author":"SK Kumar","year":"2020","unstructured":"Kumar SK, Jacobus SJ, Cohen AD, Weiss M, Callander N, Singh AK, Parker TL, Menter A, Yang X, Parsons B, Kumar P, Kapoor P, Rosenberg A, Zonder JA, Faber E Jr, Lonial S, Anderson KC, Richardson PG, Orlowski RZ, Wagner LI, Rajkumar SV. Carfilzomib or bortezomib in combination with lenalidomide and dexamethasone for patients with newly diagnosed multiple myeloma without intention for immediate autologous stem-cell transplantation (ENDURANCE): a multicentre, open-label, phase 3, randomised, controlled trial. Lancet Oncol 2020; 21(10): 1317\u20131330","journal-title":"Lancet Oncol"},{"issue":"6","key":"1184_CR41","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1182\/blood-2018-03-840132","volume":"132","author":"BA Walker","year":"2018","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies FE, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan GJ. Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma. Blood 2018; 132(6): 587\u2013597","journal-title":"Blood"},{"issue":"1","key":"1184_CR42","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1038\/s41375-018-0196-8","volume":"33","author":"BA Walker","year":"2019","unstructured":"Walker BA, Mavrommatis K, Wardell CP, Ashby TC, Bauer M, Davies F, Rosenthal A, Wang H, Qu P, Hoering A, Samur M, Towfic F, Ortiz M, Flynt E, Yu Z, Yang Z, Rozelle D, Obenauer J, Trotter M, Auclair D, Keats J, Bolli N, Fulciniti M, Szalat R, Moreau P, Durie B, Stewart AK, Goldschmidt H, Raab MS, Einsele H, Sonneveld P, San Miguel J, Lonial S, Jackson GH, Anderson KC, Avet-Loiseau H, Munshi N, Thakurta A, Morgan G. A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis. Leukemia 2019; 33(1): 159\u2013170","journal-title":"Leukemia"},{"issue":"1","key":"1184_CR43","doi-asserted-by":"publisher","first-page":"2943","DOI":"10.1038\/s41467-018-05348-5","volume":"9","author":"J Ubels","year":"2018","unstructured":"Ubels J, Sonneveld P, van Beers EH, Broijl A, van Vliet MH, de Ridder J. Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects. Nat Commun 2018; 9(1): 2943","journal-title":"Nat Commun"},{"issue":"29","key":"1184_CR44","doi-asserted-by":"publisher","first-page":"4798","DOI":"10.1200\/JCO.2007.13.8545","volume":"26","author":"O Decaux","year":"2008","unstructured":"Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients: a study of the Intergroupe Francophone du Myelome. J Clin Oncol 2008; 26(29): 4798\u20134805","journal-title":"J Clin Oncol"},{"issue":"9","key":"1184_CR45","doi-asserted-by":"publisher","first-page":"1221","DOI":"10.1001\/jamaoncol.2018.2128","volume":"4","author":"AJ Cowan","year":"2018","unstructured":"Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP, Foreman K, Gupta R, Harvey J, Hosgood HD, Jakovljevic M, Khader Y, Linn S, Lad D, Mantovani L, Nong VM, Mokdad A, Naghavi M, Postma M, Roshandel G, Shackelford K, Sisay M, Nguyen CT, Tran TT, Xuan BT, Ukwaja KN, Vollset SE, Weiderpass E, Libby EN, Fitzmaurice C. Global burden of multiple myeloma: a systematic analysis for the Global Burden of Disease Study 2016. JAMA Oncol 2018; 4(9): 1221\u20131227","journal-title":"JAMA Oncol"},{"issue":"11","key":"1184_CR46","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1038\/nm.3708","volume":"20","author":"A Sistigu","year":"2014","unstructured":"Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, Vitale I, Goubar A, Baracco EE, Rem\u00e9dios C, Fend L, Hannani D, Aymeric L, Ma Y, Niso-Santano M, Kepp O, Schultze JL, T\u00fcting T, Belardelli F, Bracci L, La Sorsa V, Ziccheddu G, Sestili P, Urbani F, Delorenzi M, Lacroix-Triki M, Quidville V, Conforti R, Spano JP, Pusztai L, Poirier-Colame V, Delaloge S, Penault-Llorca F, Ladoire S, Arnould L, Cyrta J, Dessoliers MC, Eggermont A, Bianchi ME, Pittet M, Engblom C, Pfirschke C, Pr\u00e9ville X, Uz\u00e8 G, Schreiber RD, Chow MT, Smyth MJ, Proietti E, Andr\u00e9 F, Kroemer G, Zitvogel L. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014; 20(11): 1301\u20131309","journal-title":"Nat Med"},{"issue":"14","key":"1184_CR47","doi-asserted-by":"publisher","first-page":"e147025","DOI":"10.1172\/JCI147025","volume":"131","author":"Y He","year":"2021","unstructured":"He Y, Wang L, Wei T, Xiao YT, Sheng H, Su H, Hollern DP, Zhang X, Ma J, Wen S, Xie H, Yan Y, Pan Y, Hou X, Tang X, Suman VJ, Carter JM, Weinshilboum R, Wang L, Kalari KR, Weroha SJ, Bryce AH, Boughey JC, Dong H, Perou CM, Ye D, Goetz MP, Ren S, Huang H. FOXA1 overexpression suppresses interferon signaling and immune response in cancer. J Clin Invest 2021; 131(14): e147025","journal-title":"J Clin Invest"},{"issue":"1","key":"1184_CR48","doi-asserted-by":"publisher","first-page":"e143296","DOI":"10.1172\/JCI143296","volume":"131","author":"M von Locquenghien","year":"2021","unstructured":"von Locquenghien M, Rozalen C, Celia-Terrassa T. Interferons in cancer immunoediting: sculpting metastasis and immunotherapy response. J Clin Invest 2021; 131(1): e143296","journal-title":"J Clin Invest"},{"issue":"3","key":"1184_CR49","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1038\/s41573-018-0011-2","volume":"18","author":"EC Borden","year":"2019","unstructured":"Borden EC. Interferons alpha and beta in cancer: therapeutic opportunities from new insights. Nat Rev Drug Discov 2019; 18(3): 219\u2013234","journal-title":"Nat Rev Drug Discov"},{"issue":"9","key":"1184_CR50","doi-asserted-by":"publisher","first-page":"3538","DOI":"10.1073\/pnas.1313814111","volume":"111","author":"Y Sun","year":"2014","unstructured":"Sun Y, Zhang W, Chen D, Lv Y, Zheng J, Lilljebjorn H, Ran L, Bao Z, Soneson C, Sj\u00f6gren HO, Salford LG, Ji J, French PJ, Fioretos T, Jiang T, Fan X. A glioma classification scheme based on coexpression modules of EGFR and PDGFRA. Proc Natl Acad Sci USA 2014; 111(9): 3538\u20133543","journal-title":"Proc Natl Acad Sci USA"},{"issue":"1","key":"1184_CR51","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/s13073-023-01175-6","volume":"15","author":"Y Wei","year":"2023","unstructured":"Wei Y, Li G, Feng J, Wu F, Zhao Z, Bao Z, Zhang W, Su X, Li J, Qi X, Duan Z, Zhang Y, Vega SF, Jakola AS, Sun Y, Car\u00e9n H, Jiang T, Fan X. Stalled oligodendrocyte differentiation in IDH-mutant gliomas. Genome Med 2023; 15(1): 24","journal-title":"Genome Med"},{"issue":"12","key":"1184_CR52","doi-asserted-by":"publisher","first-page":"5495","DOI":"10.1007\/s00277-024-06009-y","volume":"103","author":"Y Yang","year":"2024","unstructured":"Yang Y, Jiang S, Du H, Tang J, Xiao P, Wu Y, Li J, Feng J, Wei Y, Samo AA, Lu X, Fan X. Distinct pathway activities are associated with prognosis and response to bortezomib-containing treatment in MCL1-M based molecular subtypes of multiple myeloma. Ann Hematol 2024; 103(12): 5495\u20135510","journal-title":"Ann Hematol"}],"container-title":["MedScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-025-1184-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11684-025-1184-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11684-025-1184-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T13:02:52Z","timestamp":1781096572000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11684-025-1184-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":52,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["1184"],"URL":"https:\/\/doi.org\/10.1007\/s11684-025-1184-9","relation":{},"ISSN":["3091-4973","3091-4981"],"issn-type":[{"value":"3091-4973","type":"print"},{"value":"3091-4981","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 December 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Conflicts of interest\n                      Sitao Jiang, Yuan Yang, Man Yao, Ayaz Ali Samo, Pengli Xiao, Qinglan Cao, Jiuyi Li, Huijuan Wang, Wenming Chen, Xuzhang Lu, Yin Wu, and Xiaolong Fan declare no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}},{"value":"The study was approved by the institutional and\/or national research ethics committees for the respective cohorts, and was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments, or comparable ethical standards. Informed consent was obtained from all patients for the cohort being included in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethics guidelines"}}]}}